Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 8:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hair Loss Clear all
Terminated Phase 3 Interventional Results available

DPCP for the Treatment of Alopecia Areata

NCT03651752
View directory record Official record
Conditions
Alopecia Areata
Interventions
Diphenylcyclopropenone (DPCP) Ointment
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Phase 3 Interventional Results available

A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

NCT03899259
View directory record Official record
Conditions
Alopecia Areata
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fremont, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

NCT07029711
View directory record Official record
Conditions
Severe Alopecia Areata
Interventions
Ritlecitinib higher dose, Ritlecitinib lower dose, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 11 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
31
States / cities
Irvine, California • Santa Ana, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Recruiting Not applicable Interventional

Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and Hair Regrowth in the Appalachian Highlands Region

NCT07422376
View directory record Official record
Conditions
Alopecia
Interventions
Paxman Scalp Cooling System
Device
Lead sponsor
Charles Mays
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Kingsport, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Recruiting Not applicable Interventional

Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors

NCT04764357
View directory record Official record
Conditions
Alopecia
Interventions
Paxman Scalp Cooling System, Alopecia Assessments, Patient Reported Outcomes Questionnaires
Device · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
7 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5%

NCT00176943
View directory record Official record
Conditions
Alopecia Areata
Interventions
Aldara Cream 5%
Drug
Lead sponsor
Hordinsky, Maria K., MD
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 25, 2026, 8:04 AM EDT
Enrolling by invitation Not applicable Interventional

To Test the Effectiveness and Implementation Approach of a 3-month PILI Pasifika Program Lifestyle Program With Components of Social Determinants of Health Activities in Real-world Settings (Clinical and Non-clinical Settings) Across 3 Years

NCT07387393
View directory record Official record
Conditions
Cardiometabolic Conditions, Hypertension (HTN), Dyslipidemia, Pre-diabetes, Type 2 Diabetes Mellitus (T2DM), Overweight (BMI > 25), Weight Loss Trial
Interventions
PILI (Partnership for Improving Lifestyle Intervention) Pasifika Program
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Fayetteville, Arkansas • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Not applicable Interventional

Point-of-Care Adipose-derived Cells for Hair Growth

NCT02729415
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Stromal Vascular Fraction Cells (SVF Cells) Injection, Liposuction, Hair Measurements
Procedure · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2019 · Synced Sep 25, 2026, 8:04 AM EDT
Recruiting Phase 2 Interventional

Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris

NCT07487948
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia, Lichen Planopilaris
Interventions
Delgocitinib
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Withdrawn Phase 2 Interventional

Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia

NCT03852992
View directory record Official record
Conditions
Male Pattern Hair Loss, Androgenetic Alopecia, Male Pattern Baldness
Interventions
Post-Laser Minoxidil 2%, At-Home Minoxidil 5%, Laser, Post-laser 5mg minoxidil, Post-laser 10mg minoxidil, Post-laser 20mg minoxidil
Drug · Device
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 65 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 25, 2026, 8:04 AM EDT
Enrolling by invitation Not applicable Interventional

Study Evaluating Xtressé Gummy Supplement in Women With Self-Perceived Thinning Hair

NCT07224555
View directory record Official record
Conditions
Hair Thinning
Interventions
Xtressé Hair Growth Gummies
Other
Lead sponsor
Restore Biologics Holdings, Inc. dba Xtressé
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Maitland, Florida • Alpharetta, Georgia • Marriottsville, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling

NCT04341363
View directory record Official record
Conditions
Androgenic Alopecia
Interventions
Tattoo machine
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

To Evaluate the Effects of Viviscal Oral Supplements When Used by Females With Self-perceived Thinning Hair

NCT02288858
View directory record Official record
Conditions
Hair Thinning
Interventions
Viviscal Oral Supplement Tablets
Dietary Supplement
Lead sponsor
Irish Response t/a Lifes2good
Industry
Eligibility
24 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Sep 25, 2026, 8:04 AM EDT
Active, not recruiting Not applicable Interventional

Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)

NCT06215469
View directory record Official record
Conditions
Breast Cancer, Early-stage Breast Cancer, Hair Loss, Alopecia, Chemotherapy-induced Alopecia
Interventions
Amma Portable Scalp Cooling System (PSCS), Questionnaires
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia

NCT00691769
View directory record Official record
Conditions
Central Centrifugal Scarring Alopecia, Lichen Planopilaris, Discoid Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
30 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Phase 2 Interventional Results available

Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)

NCT03315689
View directory record Official record
Conditions
Alopecia Universalis (AU), Alopecia Totalis (AT)
Interventions
Vehicle, ATI-50002
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss

NCT01325350
View directory record Official record
Conditions
Alopecia, Baldness
Interventions
bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C, bimatoprost vehicle solution, minoxidil 2% solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 59 Years · Female only
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Sep 25, 2026, 8:04 AM EDT
Active, not recruiting No phase listed Observational

Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

NCT06531109
View directory record Official record
Conditions
Alopecia Areata
Interventions
Ritlecitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
28
States / cities
Birmingham, Alabama • Montgomery, Alabama • Fremont, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Not yet recruiting Phase 4 Interventional

Effect of Platelet-Rich Plasma Versus Placebo in the Treatment of Central Centrifugal Cicatricial Alopecia

NCT06998433
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia
Interventions
Platelet-Rich Plasma (PRP) Injections, Saline
Biological · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 25, 2026, 8:04 AM EDT
Active, not recruiting No phase listed Observational

Endocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer Patients

NCT05612100
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Electronic Health Record Review, Questionnaire Administration, Survey Administration
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
23
States / cities
Albert Lea, Minnesota • Baxter, Minnesota • Bemidji, Minnesota + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 25, 2026, 8:04 AM EDT
Active, not recruiting Phase 2 Interventional

Use of Botulinum Toxin in the Treatment of Androgenic Alopecia

NCT05456087
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
incobotulinumtoxin A
Drug
Lead sponsor
Zel Skin and Laser Specialists
Other
Eligibility
22 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Edina, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Early Phase 1 Interventional

Keratinocyte Growth Factor- Hair Serum for the Prevention of Chemotherapy Induced Alopecia

NCT04554732
View directory record Official record
Conditions
Alopecia, Chemotherapy-Induced Change, Hair Loss, Alopecia Drugs
Interventions
Keratinocyte growth factor
Drug
Lead sponsor
University of Arizona
Other
Eligibility
21 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Not applicable Interventional

Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss

NCT06149221
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
NTAP
Device
Lead sponsor
Dr. Peter C. Friedman
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 25, 2026, 8:04 AM EDT
Completed Early Phase 1 Interventional

Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia

NCT03346668
View directory record Official record
Conditions
Scarring Alopecia, Frontal Fibrosing Alopecia, Lichen Planopilaris, Central Centrifugal Cicatricial Alopecia, Central Centrifugal Scarring Alopecia
Interventions
Topical gabapentin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Sep 25, 2026, 8:04 AM EDT